{"id":"amprotropine","rwe":[{"pmid":"931459","year":"1977","title":"Atropine substitutes and the writhing syndrome in mice.","finding":"","journal":"Archives internationales de pharmacodynamie et de therapie","studyType":"Clinical Study"},{"pmid":"15431505","year":"1950","title":"The use of amprotropine (Bayer's brand of hexamine camphorate) in the treatment of hard-pad disease in dogs.","finding":"","journal":"The Veterinary record","studyType":"Clinical Study"}],"tags":[{"label":"amprotropine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["amprotropine phosphate","amprotropine"],"offLabel":[],"synonyms":["amprotropine phosphate","amprotropine"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"amprotropine","explanation":"Imagine your body's cells have locks on them, and amprotropine is a key that fits into those locks. When it binds to the lock, it triggers a series of events that ultimately lead to the desired therapeutic outcome. However, the exact details of how amprotropine interacts with its target are not well understood.","oneSentence":"Amprotropine is thought to work by interacting with a specific molecular target to produce a therapeutic effect.","technicalDetail":"Amprotropine is a small molecule that binds to a specific protein or receptor, altering its function and leading to a downstream effect on cellular processes."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3675","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=amprotropine","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:43:22.604758","biosimilars":[],"competitors":[],"genericName":"amprotropine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"001757","UNII":"Q1S268DPRS","CHEBI":"CHEBI:2685","UMLSCUI":"C0164771","ChEMBL_ID":"CHEMBL4302313","PUBCHEM_CID":"8645","SNOMEDCT_US":"79689000","SECONDARY_CAS_RN":"134-53-2","MESH_SUPPLEMENTAL_RECORD_UI":"C053014"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1977 Sep","pmid":"931459","title":"Atropine substitutes and the writhing syndrome in mice.","journal":"Archives internationales de pharmacodynamie et de therapie"},{"date":"1950 Aug 5","pmid":"15431505","title":"The use of amprotropine (Bayer's brand of hexamine camphorate) in the treatment of hard-pad disease in dogs.","journal":"The Veterinary record"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"amprotropine","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Amprotropine is a small molecule drug of the amprotropine class, but specific details about its development, commercial status, and approved indications are not available. As a result, there is limited information on its target, pharmacokinetics, and safety profile. Further research is needed to understand its mechanism of action and clinical applications. Amprotropine's commercial status, including patent status and generic availability, is also unclear. Overall, amprotropine appears to be a relatively unknown compound.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}